| UHC UMR Medical and Drug | Breast Reconstruction – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gazyva® (Obinutuzumab) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Natalizumab (Tyruko® & Tysabri®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Experimental Technologies | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Gastric Electrical Stimulation | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Hyaluronate Derivatives (Viscosupplementation) | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Implantable Hypoglossal Nerve Stimulation | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | D. Centene clinical policy | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Non-Myeloablative Allogeneic Stem Cell Transplants | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Pancreas Transplantation | 2026-01-01 |